Yoshida K, et al. - Researchers designed this randomized phase III study to compare postoperative S-1 plus docetaxel with S-1 alone for R0 resection of pathologic stage III gastric cancer. They performed the second interim analysis when the number of events reached 216 among 915 enrolled patients (median follow-up, 12.5 months). Outcomes revealed that in patients with stage III gastric cancer, docetaxel addition to S-1 is effective with few safety concerns. The applicability of the present findings in countries in which perioperative adjuvant chemotherapy or chemoradiation is not standard is supported.